A revolutionary medical device in the field of cardiology, significantly improving the quality of life of patients with degenerative or congenital valve disease.
Artificial aortic valve
Novostia, a Swiss startup founded in 2017, has entrusted MPS with the manufacture of its TRIFLO artificial valve, a revolutionary aortic prosthesis on several levels. Thanks to its aerodynamic design, the presence of three leaflets and the absence of physical pivot axes for the leaflets, the TRIFLO valve aims to satisfy the following three criteria:
The TRIFLO device is in clinical trial and is not approved for sale.
*only demonstrated in vitro
The TRIFLO valve offers many advantages over mechanical and biological artificial valves on the market. From the outset of Novostia's development, MPS has been guided by the fundamental requirements determined by the functioning of a human heart.
In addition, to meet stringent tolerances on size, shape, surface finish and appearance, MPS has developed specific manufacturing processes, including milling of three-dimensional shapes to tolerances of less than 10 μm. Watchmaking-quality polishing has resulted in a degree of finish that promotes blood flow without the risk of clot formation.
The successful first clinical trials took place at the end of 2023 (read more), in Vilnius, Lithuania, a city and country that guarantee compliance with the European directive applying to medical devices and the highest quality of care. Marketing of the valve is scheduled for 2028.
Contact us now if you need our help for your project.
